Annual FIT Testing Detects Colorectal Cancer Two Years Earlier Than Colonoscopy Alone, Study of High-Risk Popula...(and more frequent colonoscopies if polyp...),Health

Date:5/20/2008

and more frequent colonoscopies if polyps are detected or a risk of hereditary nonpolyposis colorectal cancer (HNPCC) is suspected. For patients at average risk over the age of 50, ACS guidelines include colonoscopy every ten years and an annual FIT test among the recommended screening options.(4)

The study was conducted using the InSure(R) FIT(TM) test, a take-at-home annual colorectal cancer screening test from Enterix, Inc., a wholly-owned subsidiary of Quest Diagnostics. InSure FIT, and the recently launched InSure Quik F I T(TM), each use a patient-friendly, long-handled blue brush to collect two water-based samples for analysis. The tests are completed at home, and samples are submitted to a Quest Diagnostics laboratory (InSure FIT) or returned to the physician's office (InSure Quik F I T) for evaluation.

The study presented at Digestive Disease Week was funded by grants from the National Health and Medical Council of Australia and Enterix Australia Pty. Ltd. Enterix was acquired by Quest Diagnostics in September 2006. Neither company participated in the study's data analysis or influenced the conclusions of the researchers.

The study abstract is published in the April 2008 supplement of Gastroenterology.

About Colorectal Cancer

Colorectal cancer is the second leading cause of cancer death in the United States. The American Cancer Society (ACS) estimates nearly 150,000 men and women in the U.S. will be diagnosed with colorectal cancer this year, and one third of these patients will ultimately succumb to the disease.(5) When found early and treated, the five-year relative survival rate for colon cancer is 90 percent(6), yet less than 40 percent of colorectal cancers are found early.(7) Medical experts advise that anyone at age 50 or older at average risk should, as one of their screening options, be screened annually with an FOBT or FIT for this disease. Recent ACS guidelines reinforce recommendations for FIT tests, like the
'/>"/>

SOURCE Quest Diagnostics Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting
2. New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nations Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
3. Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
4. Eisais Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting
5. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
6. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
7. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
8. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
10. Kosan Announces Data Presentations at ASCO 2008 Annual Meeting
11. Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting